The new generation of recombinant viral subunit vaccines

Current Opinion in Biotechnology

Volumn 7, Issue 6, 1996, Pages 646-652

  Ellis, Ronald W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ROTAVIRUS VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN EXPRESSION; CYTOMEGALOVIRUS; DENGUE VIRUS; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; INFLUENZA VIRUS; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; ROTAVIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS RECOMBINANT; WART VIRUS;

CYTOMEGALOVIRUS; DENGUE VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; INFLUENZA VIRUS; RESPIRATORY SYNCYTIAL VIRUS; ROTAVIRUS; SIMPLEXVIRUS;

EID: 0030560642     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(96)80077-2     Document Type: Article

References (52)

1. Ellis RW. New technologies for making vaccines. Plotkin SA, Mortimer EA. edn 2 Vaccines. 1994;867-888 WB Saunders Company, Philadelphia.
2. Britt W, Fay J, Seals J, Kensil C. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J Infect Dis. 171:1995;18-25.
3. Kensil CR, Patel U, Lennick M, Marciane D. Separation and characterization of saponins with adjuvant activity from Quilajja saponaria molina cortex. J Immunol. 146:1991;431-437.
4. Delenda C, Frenkiel MP, Deubel V. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus-infected insect cells. Arch Virol. 139:1994;197-207.
5. Feighny R, Burrous J, Putnak R. Dengue virus type-2 envelope protein made using recombinant baculovirus protects mice against viral challenge. Am J Trop Med Hyg. 50:1994;322-328.
6. Eckels KH, Dubois DR, Summers PI, Schlesinger JJ, Shelly M, Cohen S, Zhang Y-M, Lai C-J, Kurane I, Rothman A, et al. Immunization of monkeys with baculovirus - dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection. Am J Trop Med Hyg. 50:1994;472-478.
7. Morgan AJ. Epstein - Barr virus vaccines. Vaccine. 10:1992;563-571.
8. Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ. Immunization of cottontop tamarins and rabbits with a candidate vaccine against Epstein - Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine. 12:1994;1180-1184.
9. Shouval D, Han Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH. Improved immunogenicity in mice of a mammalian cell-derived hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 12:1994;1453-1459.
10. Raz R, Dagan R, Galil A, Brill G, Kassis I, Koren R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine. 14:1996;207-211.
11. Thanavala Y, Yang Y-F, Lyons P, Mason HS, Arntzen C. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. of special interest Proc Natl Acad Sci USA. 92:1995;3358-3361 This study shows the feasibility of producing a vaccine antigen in plants and may offer long-term promise for orally delivered vaccines.
12. Motti CM, Nuzzo A, Meola A, Galfre G, Felici F, Cortese R, Nicosia A, Monaci P. Recognition by human sera and immunogenicity of HBsAg mimetopes selected from an M13 phage display library. Gene. 1996;. in press.
13. Meola A, Delmastro P, Monaci P, Luzzago A, Nicosia A, Felici F, Cortese R, Galfre G. Derivation of vaccines from mimetopes: immunologic properties of human hepatitis B surface antigen mimetopes displayed on filamentous phage. J Immunol. 154:1995;3162-3172.
14. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
15. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Lelby M, Kuo G, Houghton M, Choo Q-L. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia virus. J Virol. 67:1993;6753-6761.
16. Choo Q-L, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA. 91:1994;1294-1298.
17. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF, Dekker CL. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1994;1460-1463.
18. Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis. 70:1994;1110-1119.
19. Langenburg AGM, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Intern Med. 122:1995;889-898.
20. Gihiasi H, Nesburn AB, Wechsler SL. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine. 14:1996;107-112.
21. Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff C. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1 SF2 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide depalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis. 170:1994;1288-1291.
22. Gorse GJ, Rogers JH, Perry JE, Newman FK, Frey SE, Patel GB, Belshe RB. HIV-1 recombinant gp160 vaccine-induced antibodies in serum and saliva. Vaccine. 13:1995;209-214.
23. Mannhalter JW, Fischer MB, Wolf HM, Kupcil Z, Barrett N, Dorner F, Eder G, Eibl MM. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells. J Infect Dis. 171:1995;437-440.
24. Rovinski B, Rodrigues L, Cao SZ, Yao F-L, McGuinnes U, Sia C, Cates G, Zolla-Pazner S, Karwowska S, Matthews TJ, et al. Induction of HIV type 1 neutralizing antibodies by immunization with genetically-engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. of special interest AIDS Res Hum Retroviruses. 10:1995;1187-1195 Virus-like particles can be created as candidate HIV-1 immunogens. Such structures often elicit antibodies against native viral epitopes more efficiently than do monomeric subunit antigens.
25. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. of special interest J Infect Dis. 173:1996;340-348 A key challenge for developing an HIV-1 vaccine is to elicit neutralizing antibodies against primary clinical isolates, given that envelope subunit vaccines elicit antibodies that neutralize only laboratory-adapted isolates.
26. McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, Greenberg PD. Immune responses elicited by recombinant vaccinia human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis. 169:1994;41-47.
27. Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB. The NIAID AIDS Vaccine Clinical Trial Network: Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine. 12:1994;912-918.
28. Pialoux G, Excler J-L, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman J-L, Matthews TJ, Meignier B, Kieny M-P, et al. A prime-boost approach to HIV preventive vaccine using recombinant canarypox virus expressing glycoprotein 160 (MN) followed by recombinant glycoprotein 160 (MN/LAI). of special interest AIDS Res Hum Retroviruses. 11:1995;373-381 A mixed immunization regimen, whereby one immunogen primes the immune response and the other boosts it, may be more effective for HIV-1 than either immunogen used per se.
29. Salmon-Ceron D, Excler J-L, Sicard D, Blanche P, Finkielstzien L, Gluckman J-C, Autran B, Matthews TJ, Meignier B, Kieny M-P, et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses. 11:1995;1479-1486.
30. Backstrom M, Lebens M, Schodel F, Holmgren I. Insertion of HIV-1 neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene. 149:1994;211-217.
31. Zhou J, Sun X-Y, Stenzel DJ, Fraser IH. Expression of vaccinia recombinant HPV-16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991;251-257.
32. Christensen ND, Hopil R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, Budgeon LR, Reed CA, Kreider JW. Assembled baculovirus-expressed human papillomavirus type 1 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high levels of neutralizing antibodies. J Gen Virol. 78:1994;2271-2276.
33. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induces the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol. 78:1994;2075-2079.
34. Heino R, Dillner J, Schwartz S. Human papillomavirus type 16 capsid proteins produced from recombinant semliki forest virus assemble into virus-like particles. Virology. 214:1995;349-359.
35. Hofmann KJ, Cook JC, Joyce JG, Brown DB, Schultz LD, George HA, Rosolowsky M, Fife KH, Jansen KJ. Sequences determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology. 209:1995;506-518.
36. Hofmann KJ, Neeper MP, Markus HZ, Brown DR, Muller M, Jansen KJ. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of virus-like particles in Saccharomyces cerevisiae. J Gen Virol. 77:1996;465-468.
37. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MAN, Finch J, Crawford L, Tommasino M. Synthesis and assembly of virus-like particles of human papillomaviruses type 6a and 16 in fission yeast Schizosaccharomyces pombe. Virology. 206:1995;126-135.
38. Heino P, Skyldberg B, Lehtinen M, Rantala I, Hagmar B, Kreider JW, Kimbauer R, Dillner J. Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol. 76:1995;1141-1153.
39. Sapp M, Volpers C, Muller M, Streeck RE. Organization of major and minor capsid proteins in human papillomavirus type 33 virus-like particles. J Gen Virol. 76:1995;2407-2412.
40. Breitbrud F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 69:1995;3959-3963.
41. Jansen KU, Rosolowski M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 13:1995;1509-1514.
42. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol. 70:1996;960-965.
43. Suzich JA, Ghim S-J, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. of special interest Proc Natl Acad Sci USA. 92:1995;11553-11557 Other animal papillomavirus-challenge models involve cutaneous infections. The demonstration of efficacy in this mucosal papillomavirus model is promising for the feasibility of a recombinant subunit vaccine approach for the prevention of genital (mucosal) HPV infections.
44. Chandrachud LM, Grindlay GJ, McGarcie GM, O'Neill BW, Wagner ER, Jarrett WFH, Campo MS. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology. 211:1995;204-208.
45. Powers DC, Smith GE, Anderson EL. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 171:1995;1595-1599.
46. Treanor JJ, Betts RF, Smith GE, Anderson EL, Hackett CS, Wilkinson BE, Belshe RB, Powers DC. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis. 173:1996;1467-1470.
47. Johansson BE, Price PM, Kilbourne ED. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinant vaccine. Vaccine. 13:1995;831-845.
48. Deroo T, Jou WM, Fiers W. Recombinant neuraminidase vaccine protects against lethal influenza. of special interest Vaccine. 14:1996;562-569 These experiments show the efficacy of an influenza recombinant subunit vaccine that utilizes a biological mechanism other than virus neutralization.
49. Olmsted RA, Elango N, Prince GA. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins in host immunity. Proc Natl Acad Sci USA. 83:1991;7462-7466.
50. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol. 61:1987;3416-3423.
51. Du R-P, Jackson GED, Wyde PR, Yan W-Y, Wang Q, Gisonni L, Sanhueza SE, Klein MH, Ewasyshyn ME. A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3. Bio-Technology. 12:1994;813-818.
52. Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou Y-J, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol. 68:1994;5945-5952.